説明
Dendritic Cell Lectin (DLEC), also known as BDCA-2, CD303, HECL, and alternatively designated as CLEC4C/CLECSF11/CLECSF7, is a 38 kDa type II transmembrane protein belonging to the C-type lectin family. The expression of DLEC is primarily restricted to plasmacytoid dendritic cells (pDCs) and is downregulated as these cells mature. pDCs are integral to the innate immune response, particularly in the production of IFN-alpha/beta upon exposure to Toll-like receptor (TLR) 7 and TLR9 agonists, such as microbial CpG DNA
Specifications
|
Cat.No. |
96514ES25 / 96514ES60 / 96514ES76 |
|
Size |
25 μg / 100 μg / 500 μg |
Components
|
Name |
96514ES25 |
96514ES60 |
96514ES76 |
|
Recombinant Human BDCA2/DLEC4C Protein,hFc Tag |
25 μg |
100 μg |
500 μg |
Performance parameters
|
Synonyms |
BDCA2,BDCA-2,CD303,CLEC4C,CLECSF11 |
|
Species |
Human |
|
Expression Sequence: |
Asn45-Ile213 with Human IgG1 Fc Tag at N-Terminus |
|
Accession |
Q8WTT0 |
|
Tag |
N-hFc Tag |
|
Expression System |
HEK293 |
|
Molecular Weight |
50-60 kDa (Reducing) |
|
Purity |
> 95% as determined by SDS-PAGE. |
|
Endotoxin |
<0.1 EU/μg |
|
Formulation |
PBS, PH7.4, 5% trehalose |
|
Appearance |
Lyophilized Powder |
|
Reconstitution |
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
Storage
Store at -25°C ~ -15°C for 1 year upon receipt; after reconstitution under aseptic conditions, the product is stable for 7 days at 2°C ~ 8°C or for 3 months at -85°C ~ -65°C.
Product Features
High Activity & Purity, Low Endotoxin, High Lot-to-Lot Consistency.
Application Example
ELISA Data:
Immobilized Purified anti-human CD303 (BDCA-2) Antibody at 2.0 μg/mL (100 μL/well) binds to BDCA2/DLEC4C Fc Chimera Protein, Human with an EC50 of 0.81–1.40 ng/mL.
Notes
1. This product is for research use only.
2. Please operate with lab coats and disposable gloves, for your safety.
Documents:
Manual
支払いとセキュリティ
お支払い情報は安全に処理されます。 クレジットカードの詳細を保存したり、クレジットカード情報にアクセスすることはありません
あなたも好きかもしれません
問い合わせ
よくある質問
この製品は研究目的のみに使用され、人間や動物の治療や診断に使用することを意図したものではありません。製品とコンテンツは、
特定のアプリケーションでは、追加のサードパーティの知的財産権が必要になる場合があります。